# PeptideScanner evidence objects: Calcitonin salmon

Every published version of the records placed with Calcitonin salmon, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json. Selected public evidence only; not medical advice.

- Objects: 57
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct01652573-calcitonin-salmon-v1"></a>

## ClinicalTrials.gov record NCT01652573

> PeptideScanner retained ClinicalTrials.gov record NCT01652573 at 2026-11-15T21:54:02.201Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.

- Evidence object: `story:clinicaltrials-gov-nct01652573-calcitonin-salmon:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01652573-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#clinicaltrials-gov-nct01652573-calcitonin-salmon-v1
- Content SHA-256: `22a04595fdf5b9fa783db1690639960483db8445951fb031f8d3f279d2d8f57f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01652573 ([`ctg-observation-nct01652573-2017-05-31-ce1662c15958`](#source-ctg-observation-nct01652573-2017-05-31-ce1662c15958))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01652573 at 2026-11-15T21:54:02.201Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was calcitonin-salmon. ([`ctg-observation-nct01652573-2017-05-31-ce1662c15958`](#source-ctg-observation-nct01652573-2017-05-31-ce1662c15958))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01652573 at 2026-11-15T21:54:02.201Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was calcitonin-salmon. ([`ctg-observation-nct01652573-2017-05-31-ce1662c15958`](#source-ctg-observation-nct01652573-2017-05-31-ce1662c15958))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01652573-2017-05-31-ce1662c15958`](#source-ctg-observation-nct01652573-2017-05-31-ce1662c15958))

### Sources

<a id="source-ctg-observation-nct01652573-2017-05-31-ce1662c15958"></a>
- **ClinicalTrials.gov record NCT01652573 · retained source version 2017-05-31:ce1662c15958da9202a96af7a21ee2a4e3ed05ef6d27aeb9085ccecd52745b99** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01652573) (`ctg-observation-nct01652573-2017-05-31-ce1662c15958`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01652573." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#clinicaltrials-gov-nct01652573-calcitonin-salmon-v1 SHA-256: 22a04595fdf5b9fa783db1690639960483db8445951fb031f8d3f279d2d8f57f.

---

<a id="clinicaltrials-gov-nct03342001-calcitonin-salmon-v1"></a>

## ClinicalTrials.gov record NCT03342001

> PeptideScanner retained ClinicalTrials.gov record NCT03342001 at 2026-11-15T21:54:02.201Z. Its registry update date was 2022-02-21, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.

- Evidence object: `story:clinicaltrials-gov-nct03342001-calcitonin-salmon:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-02-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03342001-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#clinicaltrials-gov-nct03342001-calcitonin-salmon-v1
- Content SHA-256: `39d8c5b6f02f7fc6e95e05774919ca29b3680fbf1d62da4fd81e8de0bc0e832d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03342001 ([`ctg-observation-nct03342001-2022-02-21-c08bd430e4d8`](#source-ctg-observation-nct03342001-2022-02-21-c08bd430e4d8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03342001 at 2026-11-15T21:54:02.201Z. Its registry update date was 2022-02-21, and PeptideScanner's reviewed identity mapping was calcitonin-salmon. ([`ctg-observation-nct03342001-2022-02-21-c08bd430e4d8`](#source-ctg-observation-nct03342001-2022-02-21-c08bd430e4d8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03342001 at 2026-11-15T21:54:02.201Z. Its registry update date was 2022-02-21, and PeptideScanner's reviewed identity mapping was calcitonin-salmon. ([`ctg-observation-nct03342001-2022-02-21-c08bd430e4d8`](#source-ctg-observation-nct03342001-2022-02-21-c08bd430e4d8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03342001-2022-02-21-c08bd430e4d8`](#source-ctg-observation-nct03342001-2022-02-21-c08bd430e4d8))

### Sources

<a id="source-ctg-observation-nct03342001-2022-02-21-c08bd430e4d8"></a>
- **ClinicalTrials.gov record NCT03342001 · retained source version 2022-02-21:c08bd430e4d8456b41cda2eb19d28732982ff4212a5bdc81fd7a5596d9b76917** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03342001) (`ctg-observation-nct03342001-2022-02-21-c08bd430e4d8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03342001." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#clinicaltrials-gov-nct03342001-calcitonin-salmon-v1 SHA-256: 39d8c5b6f02f7fc6e95e05774919ca29b3680fbf1d62da4fd81e8de0bc0e832d.

---

<a id="clinicaltrials-gov-nct03812991-calcitonin-salmon-v1"></a>

## ClinicalTrials.gov record NCT03812991

> PeptideScanner retained ClinicalTrials.gov record NCT03812991 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-06-11, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.

- Evidence object: `story:clinicaltrials-gov-nct03812991-calcitonin-salmon:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03812991-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#clinicaltrials-gov-nct03812991-calcitonin-salmon-v1
- Content SHA-256: `b2245ceb8c87e135f5620658eb68d635bf79f2726a14218091a5ec0b784e8aa7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03812991 ([`ctg-observation-nct03812991-2024-06-11-bdfe849cebdb`](#source-ctg-observation-nct03812991-2024-06-11-bdfe849cebdb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03812991 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-06-11, and PeptideScanner's reviewed identity mapping was calcitonin-salmon. ([`ctg-observation-nct03812991-2024-06-11-bdfe849cebdb`](#source-ctg-observation-nct03812991-2024-06-11-bdfe849cebdb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03812991 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-06-11, and PeptideScanner's reviewed identity mapping was calcitonin-salmon. ([`ctg-observation-nct03812991-2024-06-11-bdfe849cebdb`](#source-ctg-observation-nct03812991-2024-06-11-bdfe849cebdb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03812991-2024-06-11-bdfe849cebdb`](#source-ctg-observation-nct03812991-2024-06-11-bdfe849cebdb))

### Sources

<a id="source-ctg-observation-nct03812991-2024-06-11-bdfe849cebdb"></a>
- **ClinicalTrials.gov record NCT03812991 · retained source version 2024-06-11:bdfe849cebdb8f5cf75c49b1042f6a5234ce36d3c5f5d3db0860cfa29b2cafbe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03812991) (`ctg-observation-nct03812991-2024-06-11-bdfe849cebdb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03812991." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#clinicaltrials-gov-nct03812991-calcitonin-salmon-v1 SHA-256: b2245ceb8c87e135f5620658eb68d635bf79f2726a14218091a5ec0b784e8aa7.

---

<a id="clinicaltrials-gov-nct03935984-calcitonin-salmon-v1"></a>

## ClinicalTrials.gov record NCT03935984

> PeptideScanner retained ClinicalTrials.gov record NCT03935984 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.

- Evidence object: `story:clinicaltrials-gov-nct03935984-calcitonin-salmon:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-09-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03935984-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#clinicaltrials-gov-nct03935984-calcitonin-salmon-v1
- Content SHA-256: `6d57e0b0e3d34e02b0a6bf89dcf70555ce841d75e5113dd1283826979d8cec00`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03935984 ([`ctg-observation-nct03935984-2024-09-19-b719cb90439a`](#source-ctg-observation-nct03935984-2024-09-19-b719cb90439a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03935984 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was calcitonin-salmon. ([`ctg-observation-nct03935984-2024-09-19-b719cb90439a`](#source-ctg-observation-nct03935984-2024-09-19-b719cb90439a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03935984 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was calcitonin-salmon. ([`ctg-observation-nct03935984-2024-09-19-b719cb90439a`](#source-ctg-observation-nct03935984-2024-09-19-b719cb90439a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03935984-2024-09-19-b719cb90439a`](#source-ctg-observation-nct03935984-2024-09-19-b719cb90439a))

### Sources

<a id="source-ctg-observation-nct03935984-2024-09-19-b719cb90439a"></a>
- **ClinicalTrials.gov record NCT03935984 · retained source version 2024-09-19:b719cb90439a0f2e6ec5ce9844b4d8bc4d079edbef78bea486d77be08dc5e32e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03935984) (`ctg-observation-nct03935984-2024-09-19-b719cb90439a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03935984." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#clinicaltrials-gov-nct03935984-calcitonin-salmon-v1 SHA-256: 6d57e0b0e3d34e02b0a6bf89dcf70555ce841d75e5113dd1283826979d8cec00.

---

<a id="fda-drugs-anda076396-v1"></a>

## Drugs@FDA application ANDA076396

> The official Drugs@FDA dataset lists original submission 1 for ANDA 076396 with status AP dated 2008-11-17, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda076396:v1`
- Evidence domain: Regulatory
- Date in source: 2008-11-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda076396/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda076396-v1
- Content SHA-256: `0ee2b61a546f85b17f45ec97d797bd2d128a5fca385809179a3a119e01433a5b`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA076396 ([`fda-drugs-anda076396-2008-11-17-99faebdd1400`](#source-fda-drugs-anda076396-2008-11-17-99faebdd1400))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 076396 with status AP dated 2008-11-17, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda076396-2008-11-17-99faebdd1400`](#source-fda-drugs-anda076396-2008-11-17-99faebdd1400))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 076396 with status AP dated 2008-11-17, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda076396-2008-11-17-99faebdd1400`](#source-fda-drugs-anda076396-2008-11-17-99faebdd1400))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda076396-2008-11-17-99faebdd1400`](#source-fda-drugs-anda076396-2008-11-17-99faebdd1400))

### Sources

<a id="source-fda-drugs-anda076396-2008-11-17-99faebdd1400"></a>
- **Drugs@FDA application ANDA076396 · original submission status AP · 2008-11-17 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA076396%22&limit=1) (`fda-drugs-anda076396-2008-11-17-99faebdd1400`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA076396." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda076396-v1 SHA-256: 0ee2b61a546f85b17f45ec97d797bd2d128a5fca385809179a3a119e01433a5b.

---

<a id="fda-drugs-anda076979-v1"></a>

## Drugs@FDA application ANDA076979

> The official Drugs@FDA dataset lists original submission 1 for ANDA 076979 with status AP dated 2009-06-08, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda076979:v1`
- Evidence domain: Regulatory
- Date in source: 2009-06-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda076979/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda076979-v1
- Content SHA-256: `efbebe69803dcdf5512fa435a7bc64aff00a1b96b356b3ae03ed93a09c67eacc`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA076979 ([`fda-drugs-anda076979-2009-06-08-8f79cfbfc559`](#source-fda-drugs-anda076979-2009-06-08-8f79cfbfc559))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 076979 with status AP dated 2009-06-08, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda076979-2009-06-08-8f79cfbfc559`](#source-fda-drugs-anda076979-2009-06-08-8f79cfbfc559))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 076979 with status AP dated 2009-06-08, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda076979-2009-06-08-8f79cfbfc559`](#source-fda-drugs-anda076979-2009-06-08-8f79cfbfc559))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda076979-2009-06-08-8f79cfbfc559`](#source-fda-drugs-anda076979-2009-06-08-8f79cfbfc559))

### Sources

<a id="source-fda-drugs-anda076979-2009-06-08-8f79cfbfc559"></a>
- **Drugs@FDA application ANDA076979 · original submission status AP · 2009-06-08 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA076979%22&limit=1) (`fda-drugs-anda076979-2009-06-08-8f79cfbfc559`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA076979." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda076979-v1 SHA-256: efbebe69803dcdf5512fa435a7bc64aff00a1b96b356b3ae03ed93a09c67eacc.

---

<a id="fda-drugs-anda209358-v1"></a>

## Drugs@FDA application ANDA209358

> The official Drugs@FDA dataset lists original submission 1 for ANDA 209358 with status AP dated 2021-11-10, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda209358:v1`
- Evidence domain: Regulatory
- Date in source: 2021-11-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda209358/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda209358-v1
- Content SHA-256: `f00daf8c788ee78f2e383c9fb48d9e40993cd314964661093160d6a428e1ad37`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA209358 ([`fda-drugs-anda209358-2021-11-10-29b1161ab73b`](#source-fda-drugs-anda209358-2021-11-10-29b1161ab73b))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 209358 with status AP dated 2021-11-10, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda209358-2021-11-10-29b1161ab73b`](#source-fda-drugs-anda209358-2021-11-10-29b1161ab73b))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 209358 with status AP dated 2021-11-10, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda209358-2021-11-10-29b1161ab73b`](#source-fda-drugs-anda209358-2021-11-10-29b1161ab73b))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda209358-2021-11-10-29b1161ab73b`](#source-fda-drugs-anda209358-2021-11-10-29b1161ab73b))

### Sources

<a id="source-fda-drugs-anda209358-2021-11-10-29b1161ab73b"></a>
- **Drugs@FDA application ANDA209358 · original submission status AP · 2021-11-10 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209358%22&limit=1) (`fda-drugs-anda209358-2021-11-10-29b1161ab73b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA209358." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda209358-v1 SHA-256: f00daf8c788ee78f2e383c9fb48d9e40993cd314964661093160d6a428e1ad37.

---

<a id="fda-drugs-anda212416-v1"></a>

## Drugs@FDA application ANDA212416

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212416 with status AP dated 2021-05-14, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212416:v1`
- Evidence domain: Regulatory
- Date in source: 2021-05-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212416/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda212416-v1
- Content SHA-256: `cde7e9e5e62a2e2cbcd6731ae6dc523492314eaee8696fadf72219d127d72773`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212416 ([`fda-drugs-anda212416-2021-05-14-c13054c00483`](#source-fda-drugs-anda212416-2021-05-14-c13054c00483))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212416 with status AP dated 2021-05-14, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda212416-2021-05-14-c13054c00483`](#source-fda-drugs-anda212416-2021-05-14-c13054c00483))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212416 with status AP dated 2021-05-14, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda212416-2021-05-14-c13054c00483`](#source-fda-drugs-anda212416-2021-05-14-c13054c00483))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212416-2021-05-14-c13054c00483`](#source-fda-drugs-anda212416-2021-05-14-c13054c00483))

### Sources

<a id="source-fda-drugs-anda212416-2021-05-14-c13054c00483"></a>
- **Drugs@FDA application ANDA212416 · original submission status AP · 2021-05-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212416%22&limit=1) (`fda-drugs-anda212416-2021-05-14-c13054c00483`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212416." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda212416-v1 SHA-256: cde7e9e5e62a2e2cbcd6731ae6dc523492314eaee8696fadf72219d127d72773.

---

<a id="fda-drugs-anda212675-v1"></a>

## Drugs@FDA application ANDA212675

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212675 with status AP dated 2024-12-05, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212675:v1`
- Evidence domain: Regulatory
- Date in source: 2024-12-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212675/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda212675-v1
- Content SHA-256: `902ae1ae462da0098cf9b316f3e1898b0931b98c38d2828a721af45acf1a8251`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212675 ([`fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c`](#source-fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212675 with status AP dated 2024-12-05, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c`](#source-fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212675 with status AP dated 2024-12-05, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c`](#source-fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c`](#source-fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c))

### Sources

<a id="source-fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c"></a>
- **Drugs@FDA application ANDA212675 · original submission status AP · 2024-12-05 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212675%22&limit=1) (`fda-drugs-anda212675-2024-12-05-eff1fa6eaa4c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212675." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda212675-v1 SHA-256: 902ae1ae462da0098cf9b316f3e1898b0931b98c38d2828a721af45acf1a8251.

---

<a id="fda-drugs-anda213766-v1"></a>

## Drugs@FDA application ANDA213766

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213766 with status AP dated 2024-09-20, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213766:v1`
- Evidence domain: Regulatory
- Date in source: 2024-09-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213766/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda213766-v1
- Content SHA-256: `7291268e32351c1d671a6e580507783a02c563053cd0794687a6f588b770b3a6`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213766 ([`fda-drugs-anda213766-2024-09-20-8c0583fb5c1d`](#source-fda-drugs-anda213766-2024-09-20-8c0583fb5c1d))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213766 with status AP dated 2024-09-20, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda213766-2024-09-20-8c0583fb5c1d`](#source-fda-drugs-anda213766-2024-09-20-8c0583fb5c1d))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213766 with status AP dated 2024-09-20, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda213766-2024-09-20-8c0583fb5c1d`](#source-fda-drugs-anda213766-2024-09-20-8c0583fb5c1d))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213766-2024-09-20-8c0583fb5c1d`](#source-fda-drugs-anda213766-2024-09-20-8c0583fb5c1d))

### Sources

<a id="source-fda-drugs-anda213766-2024-09-20-8c0583fb5c1d"></a>
- **Drugs@FDA application ANDA213766 · original submission status AP · 2024-09-20 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213766%22&limit=1) (`fda-drugs-anda213766-2024-09-20-8c0583fb5c1d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213766." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda213766-v1 SHA-256: 7291268e32351c1d671a6e580507783a02c563053cd0794687a6f588b770b3a6.

---

<a id="fda-drugs-anda215715-v1"></a>

## Drugs@FDA application ANDA215715

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215715 with status AP dated 2024-04-11, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215715:v1`
- Evidence domain: Regulatory
- Date in source: 2024-04-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215715/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda215715-v1
- Content SHA-256: `bd5509d5c4eaba1b10b438b1888b9b91b4e711c633e4ae74e36304ca52b1b2ee`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215715 ([`fda-drugs-anda215715-2024-04-11-599c182c06d8`](#source-fda-drugs-anda215715-2024-04-11-599c182c06d8))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215715 with status AP dated 2024-04-11, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda215715-2024-04-11-599c182c06d8`](#source-fda-drugs-anda215715-2024-04-11-599c182c06d8))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215715 with status AP dated 2024-04-11, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda215715-2024-04-11-599c182c06d8`](#source-fda-drugs-anda215715-2024-04-11-599c182c06d8))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215715-2024-04-11-599c182c06d8`](#source-fda-drugs-anda215715-2024-04-11-599c182c06d8))

### Sources

<a id="source-fda-drugs-anda215715-2024-04-11-599c182c06d8"></a>
- **Drugs@FDA application ANDA215715 · original submission status AP · 2024-04-11 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215715%22&limit=1) (`fda-drugs-anda215715-2024-04-11-599c182c06d8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215715." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda215715-v1 SHA-256: bd5509d5c4eaba1b10b438b1888b9b91b4e711c633e4ae74e36304ca52b1b2ee.

---

<a id="fda-drugs-anda215864-v1"></a>

## Drugs@FDA application ANDA215864

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215864 with status AP dated 2026-03-04, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215864:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215864/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda215864-v1
- Content SHA-256: `b0398c22d49ab553640d5d95ec58263ece81e429d707c795015b067a738d64f8`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215864 ([`fda-drugs-anda215864-2026-03-04-a31e1d18062c`](#source-fda-drugs-anda215864-2026-03-04-a31e1d18062c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215864 with status AP dated 2026-03-04, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda215864-2026-03-04-a31e1d18062c`](#source-fda-drugs-anda215864-2026-03-04-a31e1d18062c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215864 with status AP dated 2026-03-04, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda215864-2026-03-04-a31e1d18062c`](#source-fda-drugs-anda215864-2026-03-04-a31e1d18062c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215864-2026-03-04-a31e1d18062c`](#source-fda-drugs-anda215864-2026-03-04-a31e1d18062c))

### Sources

<a id="source-fda-drugs-anda215864-2026-03-04-a31e1d18062c"></a>
- **Drugs@FDA application ANDA215864 · original submission status AP · 2026-03-04 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215864%22&limit=1) (`fda-drugs-anda215864-2026-03-04-a31e1d18062c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215864." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda215864-v1 SHA-256: b0398c22d49ab553640d5d95ec58263ece81e429d707c795015b067a738d64f8.

---

<a id="fda-drugs-anda216294-v1"></a>

## Drugs@FDA application ANDA216294

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216294 with status AP dated 2025-09-26, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216294:v1`
- Evidence domain: Regulatory
- Date in source: 2025-09-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216294/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda216294-v1
- Content SHA-256: `a49820118f77c25d376a30e0b33baaa018518cef6a2b036706020147f4919b70`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216294 ([`fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a`](#source-fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216294 with status AP dated 2025-09-26, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a`](#source-fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216294 with status AP dated 2025-09-26, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a`](#source-fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a`](#source-fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a))

### Sources

<a id="source-fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a"></a>
- **Drugs@FDA application ANDA216294 · original submission status AP · 2025-09-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216294%22&limit=1) (`fda-drugs-anda216294-2025-09-26-a6d5fe4cb35a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216294." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda216294-v1 SHA-256: a49820118f77c25d376a30e0b33baaa018518cef6a2b036706020147f4919b70.

---

<a id="fda-drugs-anda216996-v1"></a>

## Drugs@FDA application ANDA216996

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216996 with status AP dated 2026-10-29, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216996:v1`
- Evidence domain: Regulatory
- Date in source: 2026-10-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216996/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda216996-v1
- Content SHA-256: `1c3be54897e21ed98d16c048793bb039f7e571a9715e837098a72589d6535fe0`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216996 ([`fda-drugs-anda216996-2026-10-29-5d3e0e12f327`](#source-fda-drugs-anda216996-2026-10-29-5d3e0e12f327))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216996 with status AP dated 2026-10-29, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda216996-2026-10-29-5d3e0e12f327`](#source-fda-drugs-anda216996-2026-10-29-5d3e0e12f327))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216996 with status AP dated 2026-10-29, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda216996-2026-10-29-5d3e0e12f327`](#source-fda-drugs-anda216996-2026-10-29-5d3e0e12f327))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216996-2026-10-29-5d3e0e12f327`](#source-fda-drugs-anda216996-2026-10-29-5d3e0e12f327))

### Sources

<a id="source-fda-drugs-anda216996-2026-10-29-5d3e0e12f327"></a>
- **Drugs@FDA application ANDA216996 · original submission status AP · 2026-10-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216996%22&limit=1) (`fda-drugs-anda216996-2026-10-29-5d3e0e12f327`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216996." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda216996-v1 SHA-256: 1c3be54897e21ed98d16c048793bb039f7e571a9715e837098a72589d6535fe0.

---

<a id="fda-drugs-anda219196-v1"></a>

## Drugs@FDA application ANDA219196

> The official Drugs@FDA dataset lists original submission 1 for ANDA 219196 with status AP dated 2025-07-09, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda219196:v1`
- Evidence domain: Regulatory
- Date in source: 2025-07-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda219196/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda219196-v1
- Content SHA-256: `03c05eedacd87f13679176d58218d7df6d08f16a7f6c5971729444207fdaa8eb`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA219196 ([`fda-drugs-anda219196-2025-07-09-3e19237153ae`](#source-fda-drugs-anda219196-2025-07-09-3e19237153ae))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 219196 with status AP dated 2025-07-09, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda219196-2025-07-09-3e19237153ae`](#source-fda-drugs-anda219196-2025-07-09-3e19237153ae))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 219196 with status AP dated 2025-07-09, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-anda219196-2025-07-09-3e19237153ae`](#source-fda-drugs-anda219196-2025-07-09-3e19237153ae))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda219196-2025-07-09-3e19237153ae`](#source-fda-drugs-anda219196-2025-07-09-3e19237153ae))

### Sources

<a id="source-fda-drugs-anda219196-2025-07-09-3e19237153ae"></a>
- **Drugs@FDA application ANDA219196 · original submission status AP · 2025-07-09 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA219196%22&limit=1) (`fda-drugs-anda219196-2025-07-09-3e19237153ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA219196." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-anda219196-v1 SHA-256: 03c05eedacd87f13679176d58218d7df6d08f16a7f6c5971729444207fdaa8eb.

---

<a id="fda-drugs-nda017769-v1"></a>

## Drugs@FDA application NDA017769

> The official Drugs@FDA dataset lists original submission 1 for NDA 017769 with status AP dated 1978-04-17, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda017769:v1`
- Evidence domain: Regulatory
- Date in source: 1978-04-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda017769/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-nda017769-v1
- Content SHA-256: `cfdee484539d48b779ec23b943274d20e60a60186f54ee8f086c999a69889a1a`

### Claims and source pins

#### Headline

Drugs@FDA application NDA017769 ([`fda-drugs-nda017769-1978-04-17-9521c204538a`](#source-fda-drugs-nda017769-1978-04-17-9521c204538a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 017769 with status AP dated 1978-04-17, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-nda017769-1978-04-17-9521c204538a`](#source-fda-drugs-nda017769-1978-04-17-9521c204538a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 017769 with status AP dated 1978-04-17, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-nda017769-1978-04-17-9521c204538a`](#source-fda-drugs-nda017769-1978-04-17-9521c204538a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda017769-1978-04-17-9521c204538a`](#source-fda-drugs-nda017769-1978-04-17-9521c204538a))

### Sources

<a id="source-fda-drugs-nda017769-1978-04-17-9521c204538a"></a>
- **Drugs@FDA application NDA017769 · original submission status AP · 1978-04-17 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA017769%22&limit=1) (`fda-drugs-nda017769-1978-04-17-9521c204538a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA017769." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-nda017769-v1 SHA-256: cfdee484539d48b779ec23b943274d20e60a60186f54ee8f086c999a69889a1a.

---

<a id="fda-drugs-nda017808-v1"></a>

## Drugs@FDA application NDA017808

> The official Drugs@FDA dataset lists original submission 1 for NDA 017808 with status AP dated 1986-07-03, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda017808:v1`
- Evidence domain: Regulatory
- Date in source: 1986-07-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda017808/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-nda017808-v1
- Content SHA-256: `9ad08006b5bf6e24d07b7e38468dfef4eb6d859c5762bee42b70569d095068a1`

### Claims and source pins

#### Headline

Drugs@FDA application NDA017808 ([`fda-drugs-nda017808-1986-07-03-b581b91d05d3`](#source-fda-drugs-nda017808-1986-07-03-b581b91d05d3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 017808 with status AP dated 1986-07-03, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-nda017808-1986-07-03-b581b91d05d3`](#source-fda-drugs-nda017808-1986-07-03-b581b91d05d3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 017808 with status AP dated 1986-07-03, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-nda017808-1986-07-03-b581b91d05d3`](#source-fda-drugs-nda017808-1986-07-03-b581b91d05d3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda017808-1986-07-03-b581b91d05d3`](#source-fda-drugs-nda017808-1986-07-03-b581b91d05d3))

### Sources

<a id="source-fda-drugs-nda017808-1986-07-03-b581b91d05d3"></a>
- **Drugs@FDA application NDA017808 · original submission status AP · 1986-07-03 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA017808%22&limit=1) (`fda-drugs-nda017808-1986-07-03-b581b91d05d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA017808." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-nda017808-v1 SHA-256: 9ad08006b5bf6e24d07b7e38468dfef4eb6d859c5762bee42b70569d095068a1.

---

<a id="fda-drugs-nda020313-v1"></a>

## Drugs@FDA application NDA020313

> The official Drugs@FDA dataset lists original submission 1 for NDA 020313 with status AP dated 1995-08-17, and names calcitonin salmon among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020313:v1`
- Evidence domain: Regulatory
- Date in source: 1995-08-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020313/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-nda020313-v1
- Content SHA-256: `9f68fa859f3e24ba59302e284454f179c1d16d793ba24c2f404945f18ae8793a`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020313 ([`fda-drugs-nda020313-1995-08-17-25f5bc77bedb`](#source-fda-drugs-nda020313-1995-08-17-25f5bc77bedb))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020313 with status AP dated 1995-08-17, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-nda020313-1995-08-17-25f5bc77bedb`](#source-fda-drugs-nda020313-1995-08-17-25f5bc77bedb))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020313 with status AP dated 1995-08-17, and names calcitonin salmon among the application record's active ingredients. ([`fda-drugs-nda020313-1995-08-17-25f5bc77bedb`](#source-fda-drugs-nda020313-1995-08-17-25f5bc77bedb))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020313-1995-08-17-25f5bc77bedb`](#source-fda-drugs-nda020313-1995-08-17-25f5bc77bedb))

### Sources

<a id="source-fda-drugs-nda020313-1995-08-17-25f5bc77bedb"></a>
- **Drugs@FDA application NDA020313 · original submission status AP · 1995-08-17 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020313%22&limit=1) (`fda-drugs-nda020313-1995-08-17-25f5bc77bedb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020313." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-nda020313-v1 SHA-256: 9f68fa859f3e24ba59302e284454f179c1d16d793ba24c2f404945f18ae8793a.

---

<a id="fda-drugs-nda021406-v1"></a>

## Drugs@FDA application NDA021406

> The official Drugs@FDA dataset lists original submission 1 for NDA 021406 with status AP dated 2005-08-12, and names calcitonin salmon recombinant among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021406:v1`
- Evidence domain: Regulatory
- Date in source: 2005-08-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021406/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-nda021406-v1
- Content SHA-256: `2b5e4c619802f91c0ac7d7eda37e6ceea623dd1ce30264245c8c3b2e83270ac8`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021406 ([`fda-drugs-nda021406-2005-08-12-561ee3afc3a2`](#source-fda-drugs-nda021406-2005-08-12-561ee3afc3a2))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021406 with status AP dated 2005-08-12, and names calcitonin salmon recombinant among the application record's active ingredients. ([`fda-drugs-nda021406-2005-08-12-561ee3afc3a2`](#source-fda-drugs-nda021406-2005-08-12-561ee3afc3a2))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021406 with status AP dated 2005-08-12, and names calcitonin salmon recombinant among the application record's active ingredients. ([`fda-drugs-nda021406-2005-08-12-561ee3afc3a2`](#source-fda-drugs-nda021406-2005-08-12-561ee3afc3a2))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021406-2005-08-12-561ee3afc3a2`](#source-fda-drugs-nda021406-2005-08-12-561ee3afc3a2))

### Sources

<a id="source-fda-drugs-nda021406-2005-08-12-561ee3afc3a2"></a>
- **Drugs@FDA application NDA021406 · original submission status AP · 2005-08-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021406%22&limit=1) (`fda-drugs-nda021406-2005-08-12-561ee3afc3a2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021406." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#fda-drugs-nda021406-v1 SHA-256: 2b5e4c619802f91c0ac7d7eda37e6ceea623dd1ce30264245c8c3b2e83270ac8.

---

<a id="federal-register-2012-22658-v1"></a>

## Federal Register notice 2012-22658

> The Federal Register published notice 2012-22658, attributed to FDA and its parent HHS department, on 2012-09-14. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

- Evidence object: `story:federal-register-2012-22658:v1`
- Evidence domain: Regulatory
- Date in source: 2012-09-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-22658/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2012-22658-v1
- Content SHA-256: `ee3092da58db4ddbc44e1d566581e49f59ec11918371cdc169c5ca8a6a660eb7`

### Claims and source pins

#### Headline

Federal Register notice 2012-22658 ([`federal-register-2012-22658-7cd1a02d614f`](#source-federal-register-2012-22658-7cd1a02d614f))

#### Summary

The Federal Register published notice 2012-22658, attributed to FDA and its parent HHS department, on 2012-09-14. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2012-22658-7cd1a02d614f`](#source-federal-register-2012-22658-7cd1a02d614f))

#### Paragraph 1

The Federal Register published notice 2012-22658, attributed to FDA and its parent HHS department, on 2012-09-14. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2012-22658-7cd1a02d614f`](#source-federal-register-2012-22658-7cd1a02d614f))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-22658-7cd1a02d614f`](#source-federal-register-2012-22658-7cd1a02d614f))

### Sources

<a id="source-federal-register-2012-22658-7cd1a02d614f"></a>
- **Federal Register notice 2012-22658 · published 2012-09-14 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-09-14/pdf/2012-22658.pdf) (`federal-register-2012-22658-7cd1a02d614f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-22658." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2012-22658-v1 SHA-256: ee3092da58db4ddbc44e1d566581e49f59ec11918371cdc169c5ca8a6a660eb7.

---

<a id="federal-register-2013-00507-v1"></a>

## Federal Register notice 2013-00507

> The Federal Register published notice 2013-00507, attributed to FDA and its parent HHS department, on 2013-01-14. Its official title is “Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

- Evidence object: `story:federal-register-2013-00507:v1`
- Evidence domain: Regulatory
- Date in source: 2013-01-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2013-00507/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2013-00507-v1
- Content SHA-256: `8ab6f2f16837bf544bb06a546fff47d4728c663f4f4c610c459061c0a01ae089`

### Claims and source pins

#### Headline

Federal Register notice 2013-00507 ([`federal-register-2013-00507-5b07ca2b4e7e`](#source-federal-register-2013-00507-5b07ca2b4e7e))

#### Summary

The Federal Register published notice 2013-00507, attributed to FDA and its parent HHS department, on 2013-01-14. Its official title is “Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2013-00507-5b07ca2b4e7e`](#source-federal-register-2013-00507-5b07ca2b4e7e))

#### Paragraph 1

The Federal Register published notice 2013-00507, attributed to FDA and its parent HHS department, on 2013-01-14. Its official title is “Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2013-00507-5b07ca2b4e7e`](#source-federal-register-2013-00507-5b07ca2b4e7e))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2013-00507-5b07ca2b4e7e`](#source-federal-register-2013-00507-5b07ca2b4e7e))

### Sources

<a id="source-federal-register-2013-00507-5b07ca2b4e7e"></a>
- **Federal Register notice 2013-00507 · published 2013-01-14 · Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2013-01-14/pdf/2013-00507.pdf) (`federal-register-2013-00507-5b07ca2b4e7e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2013-00507." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2013-00507-v1 SHA-256: 8ab6f2f16837bf544bb06a546fff47d4728c663f4f4c610c459061c0a01ae089.

---

<a id="federal-register-2018-25187-v1"></a>

## Federal Register notice 2018-25187

> The Federal Register published notice 2018-25187, attributed to FDA and its parent HHS department, on 2018-11-19. Its official title is “Determination That REGITINE (Phentolamine Mesylate) Injection, 5 Milligrams/Vial, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

- Evidence object: `story:federal-register-2018-25187:v1`
- Evidence domain: Regulatory
- Date in source: 2018-11-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-25187/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2018-25187-v1
- Content SHA-256: `d8a792fe0c8511844addce05fa2316ae402877444400f39e25e3b69b5e0749cd`

### Claims and source pins

#### Headline

Federal Register notice 2018-25187 ([`federal-register-2018-25187-1301beb3488c`](#source-federal-register-2018-25187-1301beb3488c))

#### Summary

The Federal Register published notice 2018-25187, attributed to FDA and its parent HHS department, on 2018-11-19. Its official title is “Determination That REGITINE (Phentolamine Mesylate) Injection, 5 Milligrams/Vial, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2018-25187-1301beb3488c`](#source-federal-register-2018-25187-1301beb3488c))

#### Paragraph 1

The Federal Register published notice 2018-25187, attributed to FDA and its parent HHS department, on 2018-11-19. Its official title is “Determination That REGITINE (Phentolamine Mesylate) Injection, 5 Milligrams/Vial, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2018-25187-1301beb3488c`](#source-federal-register-2018-25187-1301beb3488c))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-25187-1301beb3488c`](#source-federal-register-2018-25187-1301beb3488c))

### Sources

<a id="source-federal-register-2018-25187-1301beb3488c"></a>
- **Federal Register notice 2018-25187 · published 2018-11-19 · Determination That REGITINE (Phentolamine Mesylate) Injection, 5 Milligrams/Vial, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-11-19/pdf/2018-25187.pdf) (`federal-register-2018-25187-1301beb3488c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2018-25187." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2018-25187-v1 SHA-256: d8a792fe0c8511844addce05fa2316ae402877444400f39e25e3b69b5e0749cd.

---

<a id="federal-register-2019-19347-v1"></a>

## Federal Register notice 2019-19347

> The Federal Register published notice 2019-19347, attributed to FDA and its parent HHS department, on 2019-09-09. Its official title is “Determination That CALCIMAR (calcitonin salmon) Injection, 200 International Units Per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

- Evidence object: `story:federal-register-2019-19347:v1`
- Evidence domain: Regulatory
- Date in source: 2019-09-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-19347/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2019-19347-v1
- Content SHA-256: `792fccbf1eca84f775e21367ecc453b3bad3848f622892417394a5858434e548`

### Claims and source pins

#### Headline

Federal Register notice 2019-19347 ([`federal-register-2019-19347-a4f49e648c7c`](#source-federal-register-2019-19347-a4f49e648c7c))

#### Summary

The Federal Register published notice 2019-19347, attributed to FDA and its parent HHS department, on 2019-09-09. Its official title is “Determination That CALCIMAR (calcitonin salmon) Injection, 200 International Units Per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2019-19347-a4f49e648c7c`](#source-federal-register-2019-19347-a4f49e648c7c))

#### Paragraph 1

The Federal Register published notice 2019-19347, attributed to FDA and its parent HHS department, on 2019-09-09. Its official title is “Determination That CALCIMAR (calcitonin salmon) Injection, 200 International Units Per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2019-19347-a4f49e648c7c`](#source-federal-register-2019-19347-a4f49e648c7c))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-19347-a4f49e648c7c`](#source-federal-register-2019-19347-a4f49e648c7c))

### Sources

<a id="source-federal-register-2019-19347-a4f49e648c7c"></a>
- **Federal Register notice 2019-19347 · published 2019-09-09 · Determination That CALCIMAR (calcitonin salmon) Injection, 200 International Units Per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-09-09/pdf/2019-19347.pdf) (`federal-register-2019-19347-a4f49e648c7c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2019-19347." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2019-19347-v1 SHA-256: 792fccbf1eca84f775e21367ecc453b3bad3848f622892417394a5858434e548.

---

<a id="federal-register-2020-23300-v1"></a>

## Federal Register notice 2020-23300

> The Federal Register published notice 2020-23300, attributed to FDA and its parent HHS department, on 2020-10-21. Its official title is “Determination That BUTISOL SODIUM (Butabarbital Sodium) Oral Tablets, 15 Milligrams, 50 Milligrams, and 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

- Evidence object: `story:federal-register-2020-23300:v1`
- Evidence domain: Regulatory
- Date in source: 2020-10-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2020-23300/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2020-23300-v1
- Content SHA-256: `8a46dab2ffc5f5b83ecf02eb51601ba69dfd02f2a727ae132ac83274e02ed889`

### Claims and source pins

#### Headline

Federal Register notice 2020-23300 ([`federal-register-2020-23300-0af1dcaa877c`](#source-federal-register-2020-23300-0af1dcaa877c))

#### Summary

The Federal Register published notice 2020-23300, attributed to FDA and its parent HHS department, on 2020-10-21. Its official title is “Determination That BUTISOL SODIUM (Butabarbital Sodium) Oral Tablets, 15 Milligrams, 50 Milligrams, and 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2020-23300-0af1dcaa877c`](#source-federal-register-2020-23300-0af1dcaa877c))

#### Paragraph 1

The Federal Register published notice 2020-23300, attributed to FDA and its parent HHS department, on 2020-10-21. Its official title is “Determination That BUTISOL SODIUM (Butabarbital Sodium) Oral Tablets, 15 Milligrams, 50 Milligrams, and 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2020-23300-0af1dcaa877c`](#source-federal-register-2020-23300-0af1dcaa877c))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2020-23300-0af1dcaa877c`](#source-federal-register-2020-23300-0af1dcaa877c))

### Sources

<a id="source-federal-register-2020-23300-0af1dcaa877c"></a>
- **Federal Register notice 2020-23300 · published 2020-10-21 · Determination That BUTISOL SODIUM (Butabarbital Sodium) Oral Tablets, 15 Milligrams, 50 Milligrams, and 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2020-10-21/pdf/2020-23300.pdf) (`federal-register-2020-23300-0af1dcaa877c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2020-23300." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2020-23300-v1 SHA-256: 8a46dab2ffc5f5b83ecf02eb51601ba69dfd02f2a727ae132ac83274e02ed889.

---

<a id="federal-register-2022-25210-v1"></a>

## Federal Register notice 2022-25210

> The Federal Register published notice 2022-25210, attributed to FDA and its parent HHS department, on 2022-11-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon and Goserelin.

- Evidence object: `story:federal-register-2022-25210:v1`
- Evidence domain: Regulatory
- Date in source: 2022-11-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2022-25210/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2022-25210-v1
- Content SHA-256: `5cf189da27f49f0870c97f2370a3d15c25fc8e61f954e5da798573b7c065b9de`

### Claims and source pins

#### Headline

Federal Register notice 2022-25210 ([`federal-register-2022-25210-00d988241cce`](#source-federal-register-2022-25210-00d988241cce))

#### Summary

The Federal Register published notice 2022-25210, attributed to FDA and its parent HHS department, on 2022-11-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon and Goserelin. ([`federal-register-2022-25210-00d988241cce`](#source-federal-register-2022-25210-00d988241cce))

#### Paragraph 1

The Federal Register published notice 2022-25210, attributed to FDA and its parent HHS department, on 2022-11-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon and Goserelin. ([`federal-register-2022-25210-00d988241cce`](#source-federal-register-2022-25210-00d988241cce))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2022-25210-00d988241cce`](#source-federal-register-2022-25210-00d988241cce))

### Sources

<a id="source-federal-register-2022-25210-00d988241cce"></a>
- **Federal Register notice 2022-25210 · published 2022-11-18 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2022-11-18/pdf/2022-25210.pdf) (`federal-register-2022-25210-00d988241cce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2022-25210." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2022-25210-v1 SHA-256: 5cf189da27f49f0870c97f2370a3d15c25fc8e61f954e5da798573b7c065b9de.

---

<a id="federal-register-2023-03389-v1"></a>

## Federal Register notice 2023-03389

> The Federal Register published notice 2023-03389, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

- Evidence object: `story:federal-register-2023-03389:v1`
- Evidence domain: Regulatory
- Date in source: 2023-02-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-03389/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2023-03389-v1
- Content SHA-256: `6bc37ac99cb247712d24943f99e114bdd2f4a5dd8dbd9b0301ebf82a00514fa8`

### Claims and source pins

#### Headline

Federal Register notice 2023-03389 ([`federal-register-2023-03389-b8f567e05b96`](#source-federal-register-2023-03389-b8f567e05b96))

#### Summary

The Federal Register published notice 2023-03389, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2023-03389-b8f567e05b96`](#source-federal-register-2023-03389-b8f567e05b96))

#### Paragraph 1

The Federal Register published notice 2023-03389, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-2023-03389-b8f567e05b96`](#source-federal-register-2023-03389-b8f567e05b96))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-03389-b8f567e05b96`](#source-federal-register-2023-03389-b8f567e05b96))

### Sources

<a id="source-federal-register-2023-03389-b8f567e05b96"></a>
- **Federal Register notice 2023-03389 · published 2023-02-17 · Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-02-17/pdf/2023-03389.pdf) (`federal-register-2023-03389-b8f567e05b96`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-03389." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-2023-03389-v1 SHA-256: 6bc37ac99cb247712d24943f99e114bdd2f4a5dd8dbd9b0301ebf82a00514fa8.

---

<a id="federal-register-e7-21886-v1"></a>

## Federal Register notice E7-21886

> The Federal Register published notice E7-21886, attributed to FDA and its parent HHS department, on 2007-11-07. Its official title is “Lederle Laboratories et al.; Withdrawal of Approval of 73 New Drug Applications and 62 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

- Evidence object: `story:federal-register-e7-21886:v1`
- Evidence domain: Regulatory
- Date in source: 2007-11-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-e7-21886/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-e7-21886-v1
- Content SHA-256: `c9415c638d3dbbccb8ed2a89847d5ac0a0c05c75a4aacb5066cbdadffd79480a`

### Claims and source pins

#### Headline

Federal Register notice E7-21886 ([`federal-register-e7-21886-7c1a727f5e85`](#source-federal-register-e7-21886-7c1a727f5e85))

#### Summary

The Federal Register published notice E7-21886, attributed to FDA and its parent HHS department, on 2007-11-07. Its official title is “Lederle Laboratories et al.; Withdrawal of Approval of 73 New Drug Applications and 62 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-e7-21886-7c1a727f5e85`](#source-federal-register-e7-21886-7c1a727f5e85))

#### Paragraph 1

The Federal Register published notice E7-21886, attributed to FDA and its parent HHS department, on 2007-11-07. Its official title is “Lederle Laboratories et al.; Withdrawal of Approval of 73 New Drug Applications and 62 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon. ([`federal-register-e7-21886-7c1a727f5e85`](#source-federal-register-e7-21886-7c1a727f5e85))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e7-21886-7c1a727f5e85`](#source-federal-register-e7-21886-7c1a727f5e85))

### Sources

<a id="source-federal-register-e7-21886-7c1a727f5e85"></a>
- **Federal Register notice E7-21886 · published 2007-11-07 · Lederle Laboratories et al.; Withdrawal of Approval of 73 New Drug Applications and 62 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2007-11-07/pdf/E7-21886.pdf) (`federal-register-e7-21886-7c1a727f5e85`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E7-21886." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#federal-register-e7-21886-v1 SHA-256: c9415c638d3dbbccb8ed2a89847d5ac0a0c05c75a4aacb5066cbdadffd79480a.

---

<a id="pubmed-pmid-11045148-calcitonin-salmon-v1"></a>

## \[Salmon calcitonin in the treatment of osteoporosis\].

> PubMed lists PMID 11045148 in Vnitrni lekarstvi as Clinical Trial, Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11045148-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11045148-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-11045148-calcitonin-salmon-v1
- Content SHA-256: `cb562ae400e4dd4f8c31f7b44c248e9ada00022a192f686375d8afbefdf734c1`

### Claims and source pins

#### Headline

\[Salmon calcitonin in the treatment of osteoporosis\]. ([`pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf`](#source-pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf))

#### Summary

PubMed lists PMID 11045148 in Vnitrni lekarstvi as Clinical Trial, Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf`](#source-pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf))

#### Paragraph 1

PubMed lists PMID 11045148 in Vnitrni lekarstvi as Clinical Trial, Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf`](#source-pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf`](#source-pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf))

### Sources

<a id="source-pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf"></a>
- **\[Salmon calcitonin in the treatment of osteoporosis\]. · retained source version 1:2016-11-24:current:c34ce0666cbf3fab489b8ff36c22a11b556302833760b8ed41d29e2964787263** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11045148/) (`pubmed-observation-pmid-11045148-2016-11-24-c34ce0666cbf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Salmon calcitonin in the treatment of osteoporosis\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-11045148-calcitonin-salmon-v1 SHA-256: cb562ae400e4dd4f8c31f7b44c248e9ada00022a192f686375d8afbefdf734c1.

---

<a id="pubmed-pmid-18071651-calcitonin-salmon-v1"></a>

## Salmon calcitonin: a review of current and future therapeutic indications.

> PubMed lists PMID 18071651 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Review, with publication-date metadata of 2007-12-11 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18071651-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18071651-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-18071651-calcitonin-salmon-v1
- Content SHA-256: `4eb039dddb03c56f38e0e8e9fa1c4296eb8ce736ca5a9ce1668c8217e7af6f3b`

### Claims and source pins

#### Headline

Salmon calcitonin: a review of current and future therapeutic indications. ([`pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973`](#source-pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973))

#### Summary

PubMed lists PMID 18071651 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Review, with publication-date metadata of 2007-12-11 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973`](#source-pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973))

#### Paragraph 1

PubMed lists PMID 18071651 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Review, with publication-date metadata of 2007-12-11 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973`](#source-pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973`](#source-pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973))

### Sources

<a id="source-pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973"></a>
- **Salmon calcitonin: a review of current and future therapeutic indications. · retained source version 1:2021-10-20:current:dc9b56ca29733010fe071ba2b59d56a5ef07fa3f5d172c4df4102eff153052b4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18071651/) (`pubmed-observation-pmid-18071651-2021-10-20-dc9b56ca2973`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Salmon calcitonin: a review of current and future therapeutic indications." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-18071651-calcitonin-salmon-v1 SHA-256: 4eb039dddb03c56f38e0e8e9fa1c4296eb8ce736ca5a9ce1668c8217e7af6f3b.

---

<a id="pubmed-pmid-2137363-calcitonin-salmon-v1"></a>

## Salmon calcitonin in the acute management of hypercalcemia.

> PubMed lists PMID 2137363 in Calcified tissue international as Comparative Study, Journal Article, Review, with publication-date metadata of 1990 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2137363-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2137363-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-2137363-calcitonin-salmon-v1
- Content SHA-256: `772b098cac5d267e2c806f008904eab2c840f32f1c82084e75ece35b0ad628ca`

### Claims and source pins

#### Headline

Salmon calcitonin in the acute management of hypercalcemia. ([`pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15`](#source-pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15))

#### Summary

PubMed lists PMID 2137363 in Calcified tissue international as Comparative Study, Journal Article, Review, with publication-date metadata of 1990 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15`](#source-pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15))

#### Paragraph 1

PubMed lists PMID 2137363 in Calcified tissue international as Comparative Study, Journal Article, Review, with publication-date metadata of 1990 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15`](#source-pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15`](#source-pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15))

### Sources

<a id="source-pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15"></a>
- **Salmon calcitonin in the acute management of hypercalcemia. · retained source version 1:2019-08-28:current:e983550d3b158f124f72a10ad77d832b21ed07413e6c50e51e447f7cac73a36e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2137363/) (`pubmed-observation-pmid-2137363-2019-08-28-e983550d3b15`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Salmon calcitonin in the acute management of hypercalcemia." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-2137363-calcitonin-salmon-v1 SHA-256: 772b098cac5d267e2c806f008904eab2c840f32f1c82084e75ece35b0ad628ca.

---

<a id="pubmed-pmid-2199180-calcitonin-salmon-v1"></a>

## \[Treatment of primary osteoporosis with calcium and salmon calcitonin\].

> PubMed lists PMID 2199180 in Deutsche medizinische Wochenschrift (1946) as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1990-08-03 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2199180-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2199180-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-2199180-calcitonin-salmon-v1
- Content SHA-256: `64b39bbcee074cb1d45e473a0124a17802a932c99fcc47da40393f1c5e5509a6`

### Claims and source pins

#### Headline

\[Treatment of primary osteoporosis with calcium and salmon calcitonin\]. ([`pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b`](#source-pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b))

#### Summary

PubMed lists PMID 2199180 in Deutsche medizinische Wochenschrift (1946) as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1990-08-03 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b`](#source-pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b))

#### Paragraph 1

PubMed lists PMID 2199180 in Deutsche medizinische Wochenschrift (1946) as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1990-08-03 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b`](#source-pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b`](#source-pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b))

### Sources

<a id="source-pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b"></a>
- **\[Treatment of primary osteoporosis with calcium and salmon calcitonin\]. · retained source version 1:2016-11-23:current:f0c82863461bfbe12b583b377b52251011c0a3fa7b1e80c24c26c12c96d96da7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2199180/) (`pubmed-observation-pmid-2199180-2016-11-23-f0c82863461b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Treatment of primary osteoporosis with calcium and salmon calcitonin\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-2199180-calcitonin-salmon-v1 SHA-256: 64b39bbcee074cb1d45e473a0124a17802a932c99fcc47da40393f1c5e5509a6.

---

<a id="pubmed-pmid-23552038-calcitonin-salmon-v1"></a>

## Experts recommend against calcitonin-salmon for postmenopausal osteoporosis.

> PubMed lists PMID 23552038 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as News, with publication-date metadata of 2013-04-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23552038-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-01-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23552038-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-23552038-calcitonin-salmon-v1
- Content SHA-256: `901a541a0b09273850d1757f2673aa627b7fb55b0db45437004e341aaba21827`

### Claims and source pins

#### Headline

Experts recommend against calcitonin-salmon for postmenopausal osteoporosis. ([`pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3`](#source-pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3))

#### Summary

PubMed lists PMID 23552038 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as News, with publication-date metadata of 2013-04-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3`](#source-pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3))

#### Paragraph 1

PubMed lists PMID 23552038 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as News, with publication-date metadata of 2013-04-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3`](#source-pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3`](#source-pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3))

### Sources

<a id="source-pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3"></a>
- **Experts recommend against calcitonin-salmon for postmenopausal osteoporosis. · retained source version 1:2019-01-01:current:8f3b9e44c6e324f281a8236c3d7bf56df00bdbe4462e88459140a0784db83c49** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23552038/) (`pubmed-observation-pmid-23552038-2019-01-01-8f3b9e44c6e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Experts recommend against calcitonin-salmon for postmenopausal osteoporosis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-23552038-calcitonin-salmon-v1 SHA-256: 901a541a0b09273850d1757f2673aa627b7fb55b0db45437004e341aaba21827.

---

<a id="pubmed-pmid-25410076-calcitonin-salmon-v1"></a>

## Salmon calcitonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis.

> PubMed lists PMID 25410076 in Pakistan journal of pharmaceutical sciences as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2014-11 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25410076-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25410076-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-25410076-calcitonin-salmon-v1
- Content SHA-256: `0579e9b18a3ac32580a337bd611c7ef1d61a37975de8f3cffd0204cb49befc5d`

### Claims and source pins

#### Headline

Salmon calcitonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis. ([`pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027`](#source-pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027))

#### Summary

PubMed lists PMID 25410076 in Pakistan journal of pharmaceutical sciences as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2014-11 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027`](#source-pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027))

#### Paragraph 1

PubMed lists PMID 25410076 in Pakistan journal of pharmaceutical sciences as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2014-11 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027`](#source-pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027`](#source-pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027))

### Sources

<a id="source-pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027"></a>
- **Salmon calcitonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis. · retained source version 1:2016-11-25:current:dfbba279d0273ecd3a50fa99059bf4dcd7eb9e7e1b69baebfd51230da8165f69** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25410076/) (`pubmed-observation-pmid-25410076-2016-11-25-dfbba279d027`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Salmon calcitonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-25410076-calcitonin-salmon-v1 SHA-256: 0579e9b18a3ac32580a337bd611c7ef1d61a37975de8f3cffd0204cb49befc5d.

---

<a id="pubmed-pmid-26438308-calcitonin-salmon-v1"></a>

## Does salmon calcitonin cause cancer? A review and meta-analysis.

> PubMed lists PMID 26438308 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-05 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26438308-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26438308-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-26438308-calcitonin-salmon-v1
- Content SHA-256: `42e7ab40aa100cc64667c7d923e33840edff8e6330f3294f60c002a15fdfeb33`

### Claims and source pins

#### Headline

Does salmon calcitonin cause cancer? A review and meta-analysis. ([`pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf`](#source-pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf))

#### Summary

PubMed lists PMID 26438308 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-05 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf`](#source-pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf))

#### Paragraph 1

PubMed lists PMID 26438308 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-05 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf`](#source-pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf`](#source-pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf))

### Sources

<a id="source-pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf"></a>
- **Does salmon calcitonin cause cancer? A review and meta-analysis. · retained source version 1:2018-11-13:current:534500c5f4bf60bb916ed9566d59611a29515327d7f8f61b0a8e765d0f27f9ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26438308/) (`pubmed-observation-pmid-26438308-2018-11-13-534500c5f4bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Does salmon calcitonin cause cancer? A review and meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-26438308-calcitonin-salmon-v1 SHA-256: 42e7ab40aa100cc64667c7d923e33840edff8e6330f3294f60c002a15fdfeb33.

---

<a id="pubmed-pmid-27189946-calcitonin-salmon-v1"></a>

## Type II Turn of Receptor-bound Salmon Calcitonin Revealed by X-ray Crystallography.

> PubMed lists PMID 27189946 in The Journal of biological chemistry as Journal Article, with publication-date metadata of 2016-05-04 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27189946-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27189946-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-27189946-calcitonin-salmon-v1
- Content SHA-256: `f1a7b7c41a8e9a04039b9098b1d59fa5081e5d06b6f0dfd33721a957980c90d1`

### Claims and source pins

#### Headline

Type II Turn of Receptor-bound Salmon Calcitonin Revealed by X-ray Crystallography. ([`pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01`](#source-pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01))

#### Summary

PubMed lists PMID 27189946 in The Journal of biological chemistry as Journal Article, with publication-date metadata of 2016-05-04 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01`](#source-pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01))

#### Paragraph 1

PubMed lists PMID 27189946 in The Journal of biological chemistry as Journal Article, with publication-date metadata of 2016-05-04 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01`](#source-pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01`](#source-pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01))

### Sources

<a id="source-pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01"></a>
- **Type II Turn of Receptor-bound Salmon Calcitonin Revealed by X-ray Crystallography. · retained source version 1:2021-02-05:current:3bbf188d2c016b213d07b93e129dc20787e2436698ab81487207ca57aa3ceb1b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27189946/) (`pubmed-observation-pmid-27189946-2021-02-05-3bbf188d2c01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Type II Turn of Receptor-bound Salmon Calcitonin Revealed by X-ray Crystallography." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-27189946-calcitonin-salmon-v1 SHA-256: f1a7b7c41a8e9a04039b9098b1d59fa5081e5d06b6f0dfd33721a957980c90d1.

---

<a id="pubmed-pmid-27842824-calcitonin-salmon-v1"></a>

## Design of chondroitin sulfate-based polyelectrolyte nanoplexes: Formation of nanocarriers with chitosan and a case study of salmon calcitonin.

> PubMed lists PMID 27842824 in Carbohydrate polymers as Journal Article, with publication-date metadata of 2016-09-13 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27842824-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27842824-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-27842824-calcitonin-salmon-v1
- Content SHA-256: `ab2f5a519d9e641cb6c29f6e1c707e0aab87d36543db7b885238ae28d9a0dd35`

### Claims and source pins

#### Headline

Design of chondroitin sulfate-based polyelectrolyte nanoplexes: Formation of nanocarriers with chitosan and a case study of salmon calcitonin. ([`pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079`](#source-pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079))

#### Summary

PubMed lists PMID 27842824 in Carbohydrate polymers as Journal Article, with publication-date metadata of 2016-09-13 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079`](#source-pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079))

#### Paragraph 1

PubMed lists PMID 27842824 in Carbohydrate polymers as Journal Article, with publication-date metadata of 2016-09-13 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079`](#source-pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079`](#source-pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079))

### Sources

<a id="source-pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079"></a>
- **Design of chondroitin sulfate-based polyelectrolyte nanoplexes: Formation of nanocarriers with chitosan and a case study of salmon calcitonin. · retained source version 1:2018-12-02:current:c0e608b42079d17828825e39971d43de40b12444d72392692ac975e931ef6bd5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27842824/) (`pubmed-observation-pmid-27842824-2018-12-02-c0e608b42079`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Design of chondroitin sulfate-based polyelectrolyte nanoplexes: Formation of nanocarriers with chitosan and a case study of salmon calcitonin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-27842824-calcitonin-salmon-v1 SHA-256: ab2f5a519d9e641cb6c29f6e1c707e0aab87d36543db7b885238ae28d9a0dd35.

---

<a id="pubmed-pmid-28955978-calcitonin-salmon-v1"></a>

## Monosialoganglioside-GM1 triggers binding of the amyloid-protein salmon calcitonin to a Langmuir membrane model mimicking the occurrence of lipid-rafts.

> PubMed lists PMID 28955978 in Biochemistry and biophysics reports as Journal Article, with publication-date metadata of 2016-10-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28955978-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-09-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28955978-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-28955978-calcitonin-salmon-v1
- Content SHA-256: `286de300764a7e5917ba2a156cd0a64a2015183de2b4098d0610d6d078a2e507`

### Claims and source pins

#### Headline

Monosialoganglioside-GM1 triggers binding of the amyloid-protein salmon calcitonin to a Langmuir membrane model mimicking the occurrence of lipid-rafts. ([`pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2`](#source-pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2))

#### Summary

PubMed lists PMID 28955978 in Biochemistry and biophysics reports as Journal Article, with publication-date metadata of 2016-10-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2`](#source-pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2))

#### Paragraph 1

PubMed lists PMID 28955978 in Biochemistry and biophysics reports as Journal Article, with publication-date metadata of 2016-10-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2`](#source-pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2`](#source-pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2))

### Sources

<a id="source-pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2"></a>
- **Monosialoganglioside-GM1 triggers binding of the amyloid-protein salmon calcitonin to a Langmuir membrane model mimicking the occurrence of lipid-rafts. · retained source version 1:2020-09-30:current:5cef41553ec28c6f404e8ada4d32e10f4994b2cb57ed8d772313eb6342075cdc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28955978/) (`pubmed-observation-pmid-28955978-2020-09-30-5cef41553ec2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Monosialoganglioside-GM1 triggers binding of the amyloid-protein salmon calcitonin to a Langmuir membrane model mimicking the occurrence of lipid-rafts." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-28955978-calcitonin-salmon-v1 SHA-256: 286de300764a7e5917ba2a156cd0a64a2015183de2b4098d0610d6d078a2e507.

---

<a id="pubmed-pmid-29947020-calcitonin-salmon-v1"></a>

## Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation.

> PubMed lists PMID 29947020 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-10 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29947020-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29947020-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-29947020-calcitonin-salmon-v1
- Content SHA-256: `536d4abd05012db9c33b8cb3a0b447dacdecaaf30afda05e5f740edc2261f5c8`

### Claims and source pins

#### Headline

Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. ([`pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed`](#source-pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed))

#### Summary

PubMed lists PMID 29947020 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-10 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed`](#source-pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed))

#### Paragraph 1

PubMed lists PMID 29947020 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-10 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed`](#source-pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed`](#source-pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed))

### Sources

<a id="source-pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed"></a>
- **Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. · retained source version 1:2018-12-17:current:a4ee255ff4edb77568c25847aa750f8d59f92614c50afa268809597270297dee** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29947020/) (`pubmed-observation-pmid-29947020-2018-12-17-a4ee255ff4ed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-29947020-calcitonin-salmon-v1 SHA-256: 536d4abd05012db9c33b8cb3a0b447dacdecaaf30afda05e5f740edc2261f5c8.

---

<a id="pubmed-pmid-31905804-calcitonin-salmon-v1"></a>

## The Interaction between Amyloid Prefibrillar Oligomers of Salmon Calcitonin and a Lipid-Raft Model: Molecular Mechanisms Leading to Membrane Damage, Ca2+-Influx and Neurotoxicity.

> PubMed lists PMID 31905804 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-12-29 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31905804-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-09-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31905804-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-31905804-calcitonin-salmon-v1
- Content SHA-256: `83cfba351915023fbea3a2274432e7ef93660b9826eebb475d4364dad64c0c79`

### Claims and source pins

#### Headline

The Interaction between Amyloid Prefibrillar Oligomers of Salmon Calcitonin and a Lipid-Raft Model: Molecular Mechanisms Leading to Membrane Damage, Ca2+-Influx and Neurotoxicity. ([`pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c`](#source-pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c))

#### Summary

PubMed lists PMID 31905804 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-12-29 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c`](#source-pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c))

#### Paragraph 1

PubMed lists PMID 31905804 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-12-29 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c`](#source-pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c`](#source-pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c))

### Sources

<a id="source-pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c"></a>
- **The Interaction between Amyloid Prefibrillar Oligomers of Salmon Calcitonin and a Lipid-Raft Model: Molecular Mechanisms Leading to Membrane Damage, Ca2+-Influx and Neurotoxicity. · retained source version 1:2020-09-22:current:7db8eca6150cd9d84019f6397cb63a7f0eec418225a4b2961b9cd336e60fd034** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31905804/) (`pubmed-observation-pmid-31905804-2020-09-22-7db8eca6150c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The Interaction between Amyloid Prefibrillar Oligomers of Salmon Calcitonin and a Lipid-Raft Model: Molecular Mechanisms Leading to Membrane Damage, Ca2+-Influx and Neurotoxicity." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-31905804-calcitonin-salmon-v1 SHA-256: 83cfba351915023fbea3a2274432e7ef93660b9826eebb475d4364dad64c0c79.

---

<a id="pubmed-pmid-31953574-calcitonin-salmon-v1"></a>

## Thermosensitive Hydrogel Based on Poly(2-Ethyl-2-Oxazoline)-Poly(D,L-Lactide)-Poly(2-Ethyl-2-Oxazoline) for Sustained Salmon Calcitonin Delivery.

> PubMed lists PMID 31953574 in AAPS PharmSciTech as Journal Article, with publication-date metadata of 2020-01-17 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31953574-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-03-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31953574-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-31953574-calcitonin-salmon-v1
- Content SHA-256: `445032cd8b3a1a8a26e38508fbf0998d69a3bb3a0005f44920d8d7d2b5544012`

### Claims and source pins

#### Headline

Thermosensitive Hydrogel Based on Poly(2-Ethyl-2-Oxazoline)-Poly(D,L-Lactide)-Poly(2-Ethyl-2-Oxazoline) for Sustained Salmon Calcitonin Delivery. ([`pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa`](#source-pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa))

#### Summary

PubMed lists PMID 31953574 in AAPS PharmSciTech as Journal Article, with publication-date metadata of 2020-01-17 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa`](#source-pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa))

#### Paragraph 1

PubMed lists PMID 31953574 in AAPS PharmSciTech as Journal Article, with publication-date metadata of 2020-01-17 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa`](#source-pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa`](#source-pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa))

### Sources

<a id="source-pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa"></a>
- **Thermosensitive Hydrogel Based on Poly(2-Ethyl-2-Oxazoline)-Poly(D,L-Lactide)-Poly(2-Ethyl-2-Oxazoline) for Sustained Salmon Calcitonin Delivery. · retained source version 1:2021-03-25:current:657ac76300fa2824dc9fd4620f0a1bcaeb71ab8b0f49ddc69f40965786c61cf7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31953574/) (`pubmed-observation-pmid-31953574-2021-03-25-657ac76300fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thermosensitive Hydrogel Based on Poly(2-Ethyl-2-Oxazoline)-Poly(D,L-Lactide)-Poly(2-Ethyl-2-Oxazoline) for Sustained Salmon Calcitonin Delivery." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-31953574-calcitonin-salmon-v1 SHA-256: 445032cd8b3a1a8a26e38508fbf0998d69a3bb3a0005f44920d8d7d2b5544012.

---

<a id="pubmed-pmid-32035146-calcitonin-salmon-v1"></a>

## Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice.

> PubMed lists PMID 32035146 in Neuropharmacology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-05 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32035146-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-04-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32035146-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-32035146-calcitonin-salmon-v1
- Content SHA-256: `0fb8ec3b9f119b69d6db004508c920a310b84f4f9e7ffdf9ff0edd12894632dd`

### Claims and source pins

#### Headline

Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice. ([`pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588`](#source-pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588))

#### Summary

PubMed lists PMID 32035146 in Neuropharmacology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-05 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588`](#source-pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588))

#### Paragraph 1

PubMed lists PMID 32035146 in Neuropharmacology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-05 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588`](#source-pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588`](#source-pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588))

### Sources

<a id="source-pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588"></a>
- **Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice. · retained source version 1:2021-04-23:current:529dbdb815882f6db60c131ec6b0de590c49356cad87a36dde73720572b9e04c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32035146/) (`pubmed-observation-pmid-32035146-2021-04-23-529dbdb81588`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-32035146-calcitonin-salmon-v1 SHA-256: 0fb8ec3b9f119b69d6db004508c920a310b84f4f9e7ffdf9ff0edd12894632dd.

---

<a id="pubmed-pmid-32247161-calcitonin-salmon-v1"></a>

## Impurities identification and quantification for calcitonin salmon by liquid chromatography-high resolution mass spectrometry.

> PubMed lists PMID 32247161 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2020-03-20 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32247161-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-03-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32247161-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-32247161-calcitonin-salmon-v1
- Content SHA-256: `19470d2afaf8dddd13b20d9ad0d3b456c993aef37782efa1a8c2b3c883b7b752`

### Claims and source pins

#### Headline

Impurities identification and quantification for calcitonin salmon by liquid chromatography-high resolution mass spectrometry. ([`pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228`](#source-pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228))

#### Summary

PubMed lists PMID 32247161 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2020-03-20 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228`](#source-pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228))

#### Paragraph 1

PubMed lists PMID 32247161 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2020-03-20 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228`](#source-pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228`](#source-pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228))

### Sources

<a id="source-pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228"></a>
- **Impurities identification and quantification for calcitonin salmon by liquid chromatography-high resolution mass spectrometry. · retained source version 1:2021-03-29:current:ebc1db2b12289e6e30b7d687ae80dce772750b4a37e7c1d493f38d89238f3ef3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32247161/) (`pubmed-observation-pmid-32247161-2021-03-29-ebc1db2b1228`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Impurities identification and quantification for calcitonin salmon by liquid chromatography-high resolution mass spectrometry." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-32247161-calcitonin-salmon-v1 SHA-256: 19470d2afaf8dddd13b20d9ad0d3b456c993aef37782efa1a8c2b3c883b7b752.

---

<a id="pubmed-pmid-3318613-calcitonin-salmon-v1"></a>

## Salmon calcitonin in the treatment of postmenopausal osteoporosis.

> PubMed lists PMID 3318613 in Annals of internal medicine as Journal Article, Review, with publication-date metadata of 1987-12 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-3318613-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-3318613-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-3318613-calcitonin-salmon-v1
- Content SHA-256: `b2ed315a700e84ede3f976d21df05eb280dc3da9f0d080d5edc089fcf3e21173`

### Claims and source pins

#### Headline

Salmon calcitonin in the treatment of postmenopausal osteoporosis. ([`pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60`](#source-pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60))

#### Summary

PubMed lists PMID 3318613 in Annals of internal medicine as Journal Article, Review, with publication-date metadata of 1987-12 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60`](#source-pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60))

#### Paragraph 1

PubMed lists PMID 3318613 in Annals of internal medicine as Journal Article, Review, with publication-date metadata of 1987-12 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60`](#source-pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60`](#source-pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60))

### Sources

<a id="source-pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60"></a>
- **Salmon calcitonin in the treatment of postmenopausal osteoporosis. · retained source version 1:2019-06-19:current:5f00b1df3c6039cf3d156d8212565d1379dfb7fe10c9abab20f699e460433e30** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/3318613/) (`pubmed-observation-pmid-3318613-2019-06-19-5f00b1df3c60`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Salmon calcitonin in the treatment of postmenopausal osteoporosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-3318613-calcitonin-salmon-v1 SHA-256: b2ed315a700e84ede3f976d21df05eb280dc3da9f0d080d5edc089fcf3e21173.

---

<a id="pubmed-pmid-3392126-calcitonin-salmon-v1"></a>

## Densitometric analysis in in vivo evaluation of synthetic salmon calcitonin activity.

> PubMed lists PMID 3392126 in Journal of clinical pharmacy and therapeutics as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1988-04 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-3392126-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-10-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-3392126-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-3392126-calcitonin-salmon-v1
- Content SHA-256: `edf7abb303b179a339c5c55df6aaffc35d0d156a8fff41849bc357ebb079858b`

### Claims and source pins

#### Headline

Densitometric analysis in in vivo evaluation of synthetic salmon calcitonin activity. ([`pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f`](#source-pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f))

#### Summary

PubMed lists PMID 3392126 in Journal of clinical pharmacy and therapeutics as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1988-04 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f`](#source-pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f))

#### Paragraph 1

PubMed lists PMID 3392126 in Journal of clinical pharmacy and therapeutics as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1988-04 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f`](#source-pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f`](#source-pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f))

### Sources

<a id="source-pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f"></a>
- **Densitometric analysis in in vivo evaluation of synthetic salmon calcitonin activity. · retained source version 1:2019-10-22:current:c3456996c16fd554dc8bc23e4a386ad0d59ece7fd71e296fe796c1b01cdeb43d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/3392126/) (`pubmed-observation-pmid-3392126-2019-10-22-c3456996c16f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Densitometric analysis in in vivo evaluation of synthetic salmon calcitonin activity." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-3392126-calcitonin-salmon-v1 SHA-256: edf7abb303b179a339c5c55df6aaffc35d0d156a8fff41849bc357ebb079858b.

---

<a id="pubmed-pmid-34745472-calcitonin-salmon-v1"></a>

## Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures.

> PubMed lists PMID 34745472 in Orthopedic reviews as Journal Article, with publication-date metadata of 2021-06-21 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34745472-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-08-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34745472-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-34745472-calcitonin-salmon-v1
- Content SHA-256: `0976113e4e0ee9cb7443426b4280d1e674eeff34e68149663a30fb591ce72978`

### Claims and source pins

#### Headline

Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures. ([`pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0`](#source-pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0))

#### Summary

PubMed lists PMID 34745472 in Orthopedic reviews as Journal Article, with publication-date metadata of 2021-06-21 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0`](#source-pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0))

#### Paragraph 1

PubMed lists PMID 34745472 in Orthopedic reviews as Journal Article, with publication-date metadata of 2021-06-21 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0`](#source-pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0`](#source-pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0))

### Sources

<a id="source-pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0"></a>
- **Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures. · retained source version 1:2022-08-05:current:5a5790900ba05e608e9667475373517f1de199983cca14a0286209ae228244c2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34745472/) (`pubmed-observation-pmid-34745472-2022-08-05-5a5790900ba0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-34745472-calcitonin-salmon-v1 SHA-256: 0976113e4e0ee9cb7443426b4280d1e674eeff34e68149663a30fb591ce72978.

---

<a id="pubmed-pmid-35540827-calcitonin-salmon-v1"></a>

## Preparation and characterization of an electrospun colon-specific delivery system for salmon calcitonin.

> PubMed lists PMID 35540827 in RSC advances as Journal Article, with publication-date metadata of 2018-03-08 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35540827-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-07-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35540827-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-35540827-calcitonin-salmon-v1
- Content SHA-256: `76d76d3607088478432c49067b522d2e7748b7b949e7de65763af7291f51b910`

### Claims and source pins

#### Headline

Preparation and characterization of an electrospun colon-specific delivery system for salmon calcitonin. ([`pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc`](#source-pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc))

#### Summary

PubMed lists PMID 35540827 in RSC advances as Journal Article, with publication-date metadata of 2018-03-08 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc`](#source-pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc))

#### Paragraph 1

PubMed lists PMID 35540827 in RSC advances as Journal Article, with publication-date metadata of 2018-03-08 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc`](#source-pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc`](#source-pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc))

### Sources

<a id="source-pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc"></a>
- **Preparation and characterization of an electrospun colon-specific delivery system for salmon calcitonin. · retained source version 1:2022-07-16:current:4be8514f81cc4fe4b8550988020c6fc1f9bc01c095a0205810e45d4645416c38** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35540827/) (`pubmed-observation-pmid-35540827-2022-07-16-4be8514f81cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Preparation and characterization of an electrospun colon-specific delivery system for salmon calcitonin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-35540827-calcitonin-salmon-v1 SHA-256: 76d76d3607088478432c49067b522d2e7748b7b949e7de65763af7291f51b910.

---

<a id="pubmed-pmid-3721646-calcitonin-salmon-v1"></a>

## Salmon calcitonin in the treatment of bone metastases.

> PubMed lists PMID 3721646 in International journal of clinical pharmacology research as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1986 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-3721646-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-3721646-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-3721646-calcitonin-salmon-v1
- Content SHA-256: `00f42b99f22fb7b4163038cfc768cf38a80c57c7d5653df885320974b348aae2`

### Claims and source pins

#### Headline

Salmon calcitonin in the treatment of bone metastases. ([`pubmed-observation-pmid-3721646-2016-11-23-74473af35e01`](#source-pubmed-observation-pmid-3721646-2016-11-23-74473af35e01))

#### Summary

PubMed lists PMID 3721646 in International journal of clinical pharmacology research as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1986 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-3721646-2016-11-23-74473af35e01`](#source-pubmed-observation-pmid-3721646-2016-11-23-74473af35e01))

#### Paragraph 1

PubMed lists PMID 3721646 in International journal of clinical pharmacology research as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1986 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-3721646-2016-11-23-74473af35e01`](#source-pubmed-observation-pmid-3721646-2016-11-23-74473af35e01))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-3721646-2016-11-23-74473af35e01`](#source-pubmed-observation-pmid-3721646-2016-11-23-74473af35e01))

### Sources

<a id="source-pubmed-observation-pmid-3721646-2016-11-23-74473af35e01"></a>
- **Salmon calcitonin in the treatment of bone metastases. · retained source version 1:2016-11-23:current:74473af35e01fa737bfb138796f60f58834e3fc861918b78f9262dae977c50fa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/3721646/) (`pubmed-observation-pmid-3721646-2016-11-23-74473af35e01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Salmon calcitonin in the treatment of bone metastases." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-3721646-calcitonin-salmon-v1 SHA-256: 00f42b99f22fb7b4163038cfc768cf38a80c57c7d5653df885320974b348aae2.

---

<a id="pubmed-pmid-38713958-calcitonin-salmon-v1"></a>

## Tuning the double lipidation of salmon calcitonin to introduce a pore-like membrane translocation mechanism.

> PubMed lists PMID 38713958 in Journal of colloid and interface science as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38713958-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-05-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38713958-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-38713958-calcitonin-salmon-v1
- Content SHA-256: `b26cea7d99de8aa0faa3d5ed1f604b638abc2cc9205168ae206a5d730f88bd62`

### Claims and source pins

#### Headline

Tuning the double lipidation of salmon calcitonin to introduce a pore-like membrane translocation mechanism. ([`pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a`](#source-pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a))

#### Summary

PubMed lists PMID 38713958 in Journal of colloid and interface science as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a`](#source-pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a))

#### Paragraph 1

PubMed lists PMID 38713958 in Journal of colloid and interface science as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a`](#source-pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a`](#source-pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a))

### Sources

<a id="source-pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a"></a>
- **Tuning the double lipidation of salmon calcitonin to introduce a pore-like membrane translocation mechanism. · retained source version 1:2024-05-25:current:ff2862c1697a2b97c5408ceb7b3efe29855b75b741752e09b2099c4fccf1f41a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38713958/) (`pubmed-observation-pmid-38713958-2024-05-25-ff2862c1697a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tuning the double lipidation of salmon calcitonin to introduce a pore-like membrane translocation mechanism." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-38713958-calcitonin-salmon-v1 SHA-256: b26cea7d99de8aa0faa3d5ed1f604b638abc2cc9205168ae206a5d730f88bd62.

---

<a id="pubmed-pmid-39862273-calcitonin-salmon-v1"></a>

## Production of biologically active recombinant salmon calcitonin in Escherichia coli and fish cell line.

> PubMed lists PMID 39862273 in Archives of microbiology as Journal Article, with publication-date metadata of 2025-01-25 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39862273-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39862273-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-39862273-calcitonin-salmon-v1
- Content SHA-256: `ee676fecc58d0809c6519a98cfe7f8f9b68014f17d695ba5018a6e998f507d19`

### Claims and source pins

#### Headline

Production of biologically active recombinant salmon calcitonin in Escherichia coli and fish cell line. ([`pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf`](#source-pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf))

#### Summary

PubMed lists PMID 39862273 in Archives of microbiology as Journal Article, with publication-date metadata of 2025-01-25 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf`](#source-pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf))

#### Paragraph 1

PubMed lists PMID 39862273 in Archives of microbiology as Journal Article, with publication-date metadata of 2025-01-25 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf`](#source-pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf`](#source-pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf))

### Sources

<a id="source-pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf"></a>
- **Production of biologically active recombinant salmon calcitonin in Escherichia coli and fish cell line. · retained source version 1:2025-05-24:current:250aa59b8cbf7d2e327e388a4f04d5498d30f3043c15abb86d872430a158a762** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39862273/) (`pubmed-observation-pmid-39862273-2025-05-24-250aa59b8cbf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Production of biologically active recombinant salmon calcitonin in Escherichia coli and fish cell line." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-39862273-calcitonin-salmon-v1 SHA-256: ee676fecc58d0809c6519a98cfe7f8f9b68014f17d695ba5018a6e998f507d19.

---

<a id="pubmed-pmid-42919113-calcitonin-salmon-v1"></a>

## Salmon calcitonin prescribing for acute phantom limb pain after amputation.

> PubMed lists PMID 42919113 in Anaesthesia as Journal Article, with publication-date metadata of 2026-10-22 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42919113-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42919113-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-42919113-calcitonin-salmon-v1
- Content SHA-256: `1ef0cb1396f6703ca54f7f341ecbd6a5f7d7864a3e1b73e84d2126e74be60e56`

### Claims and source pins

#### Headline

Salmon calcitonin prescribing for acute phantom limb pain after amputation. ([`pubmed-observation-pmid-42919113-2026-10-23-1690992bb116`](#source-pubmed-observation-pmid-42919113-2026-10-23-1690992bb116))

#### Summary

PubMed lists PMID 42919113 in Anaesthesia as Journal Article, with publication-date metadata of 2026-10-22 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42919113-2026-10-23-1690992bb116`](#source-pubmed-observation-pmid-42919113-2026-10-23-1690992bb116))

#### Paragraph 1

PubMed lists PMID 42919113 in Anaesthesia as Journal Article, with publication-date metadata of 2026-10-22 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42919113-2026-10-23-1690992bb116`](#source-pubmed-observation-pmid-42919113-2026-10-23-1690992bb116))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42919113-2026-10-23-1690992bb116`](#source-pubmed-observation-pmid-42919113-2026-10-23-1690992bb116))

### Sources

<a id="source-pubmed-observation-pmid-42919113-2026-10-23-1690992bb116"></a>
- **Salmon calcitonin prescribing for acute phantom limb pain after amputation. · retained source version 1:2026-10-23:current:1690992bb1169a7d020add9da0a87f52f08dfa98dd9ad446aa5109f2106eebce** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42919113/) (`pubmed-observation-pmid-42919113-2026-10-23-1690992bb116`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Salmon calcitonin prescribing for acute phantom limb pain after amputation." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-42919113-calcitonin-salmon-v1 SHA-256: 1ef0cb1396f6703ca54f7f341ecbd6a5f7d7864a3e1b73e84d2126e74be60e56.

---

<a id="pubmed-pmid-6376042-calcitonin-salmon-v1"></a>

## \[Salmon calcitonin in metastatic bone pain. Demonstration of acute analgesia in tumor patients\].

> PubMed lists PMID 6376042 in Deutsche medizinische Wochenschrift (1946) as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1984-06-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-6376042-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-6376042-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-6376042-calcitonin-salmon-v1
- Content SHA-256: `cce8abd6bce5bfe93135bddd96d763813a30be4268b117c2f59680709ae850db`

### Claims and source pins

#### Headline

\[Salmon calcitonin in metastatic bone pain. Demonstration of acute analgesia in tumor patients\]. ([`pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6`](#source-pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6))

#### Summary

PubMed lists PMID 6376042 in Deutsche medizinische Wochenschrift (1946) as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1984-06-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6`](#source-pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6))

#### Paragraph 1

PubMed lists PMID 6376042 in Deutsche medizinische Wochenschrift (1946) as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1984-06-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6`](#source-pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6`](#source-pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6))

### Sources

<a id="source-pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6"></a>
- **\[Salmon calcitonin in metastatic bone pain. Demonstration of acute analgesia in tumor patients\]. · retained source version 1:2007-11-15:current:1a6eeca5e5a62e99a3da46249fe506f6f3b424381cd8bc29a1270d7d5e569657** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/6376042/) (`pubmed-observation-pmid-6376042-2007-11-15-1a6eeca5e5a6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Salmon calcitonin in metastatic bone pain. Demonstration of acute analgesia in tumor patients\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-6376042-calcitonin-salmon-v1 SHA-256: cce8abd6bce5bfe93135bddd96d763813a30be4268b117c2f59680709ae850db.

---

<a id="pubmed-pmid-7042129-calcitonin-salmon-v1"></a>

## Deterioration of renal bone disease in patients treated with salmon calcitonin.

> PubMed lists PMID 7042129 in Clinical endocrinology as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1982-01 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7042129-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7042129-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-7042129-calcitonin-salmon-v1
- Content SHA-256: `f70c92108b84fb06cfb597c4eabebbf6ae743b9a56b85397610e0eb296b9ba31`

### Claims and source pins

#### Headline

Deterioration of renal bone disease in patients treated with salmon calcitonin. ([`pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711`](#source-pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711))

#### Summary

PubMed lists PMID 7042129 in Clinical endocrinology as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1982-01 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711`](#source-pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711))

#### Paragraph 1

PubMed lists PMID 7042129 in Clinical endocrinology as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1982-01 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711`](#source-pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711`](#source-pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711))

### Sources

<a id="source-pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711"></a>
- **Deterioration of renal bone disease in patients treated with salmon calcitonin. · retained source version 1:2019-08-13:current:e1d316c6d711cef1d5b325f68eb039af97ea5750891de264a6452cc596cb4749** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7042129/) (`pubmed-observation-pmid-7042129-2019-08-13-e1d316c6d711`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Deterioration of renal bone disease in patients treated with salmon calcitonin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-7042129-calcitonin-salmon-v1 SHA-256: f70c92108b84fb06cfb597c4eabebbf6ae743b9a56b85397610e0eb296b9ba31.

---

<a id="pubmed-pmid-7603605-calcitonin-salmon-v1"></a>

## \[Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis\].

> PubMed lists PMID 7603605 in Minerva medica as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7603605-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7603605-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-7603605-calcitonin-salmon-v1
- Content SHA-256: `27fb536ce191ab87148fb85e56a1081b8812a40d1ec1e17dfda5ef3d0483a55d`

### Claims and source pins

#### Headline

\[Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis\]. ([`pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e`](#source-pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e))

#### Summary

PubMed lists PMID 7603605 in Minerva medica as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e`](#source-pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e))

#### Paragraph 1

PubMed lists PMID 7603605 in Minerva medica as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e`](#source-pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e`](#source-pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e))

### Sources

<a id="source-pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e"></a>
- **\[Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis\]. · retained source version 1:2016-11-23:current:b92a39df035eb3be6002b647127265038fff3dd523d79e8c814ddd2d41f60524** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7603605/) (`pubmed-observation-pmid-7603605-2016-11-23-b92a39df035e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-7603605-calcitonin-salmon-v1 SHA-256: 27fb536ce191ab87148fb85e56a1081b8812a40d1ec1e17dfda5ef3d0483a55d.

---

<a id="pubmed-pmid-7750020-calcitonin-salmon-v1"></a>

## Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.

> PubMed lists PMID 7750020 in Calcified tissue international as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7750020-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7750020-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-7750020-calcitonin-salmon-v1
- Content SHA-256: `5670f7096b816d87202cda714bd042b11e7cc1d7a4fca0c663d78ad7d9f0abed`

### Claims and source pins

#### Headline

Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. ([`pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25`](#source-pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25))

#### Summary

PubMed lists PMID 7750020 in Calcified tissue international as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25`](#source-pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25))

#### Paragraph 1

PubMed lists PMID 7750020 in Calcified tissue international as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-03 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25`](#source-pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25`](#source-pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25))

### Sources

<a id="source-pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25"></a>
- **Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. · retained source version 1:2019-08-30:current:15735a0dce25ba8d0172ce7ae6217c08432a65cb6c6dde8d743c0c110092af4c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7750020/) (`pubmed-observation-pmid-7750020-2019-08-30-15735a0dce25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-7750020-calcitonin-salmon-v1 SHA-256: 5670f7096b816d87202cda714bd042b11e7cc1d7a4fca0c663d78ad7d9f0abed.

---

<a id="pubmed-pmid-8883119-calcitonin-salmon-v1"></a>

## Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study.

> PubMed lists PMID 8883119 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8883119-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-03-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8883119-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-8883119-calcitonin-salmon-v1
- Content SHA-256: `6dfaf4e39278ffec5b9b36934fc4b5aae69c745b345d38237718846193bb839c`

### Claims and source pins

#### Headline

Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study. ([`pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8`](#source-pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8))

#### Summary

PubMed lists PMID 8883119 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8`](#source-pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8))

#### Paragraph 1

PubMed lists PMID 8883119 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8`](#source-pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8`](#source-pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8))

### Sources

<a id="source-pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8"></a>
- **Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study. · retained source version 1:2020-03-04:current:d7b1709600b8c80c1d67d695fa8096086d4952d0cda5eb1e47d784271e6dc0d8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8883119/) (`pubmed-observation-pmid-8883119-2020-03-04-d7b1709600b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-8883119-calcitonin-salmon-v1 SHA-256: 6dfaf4e39278ffec5b9b36934fc4b5aae69c745b345d38237718846193bb839c.

---

<a id="pubmed-pmid-9312206-calcitonin-salmon-v1"></a>

## Intrapulmonary drug delivery of salmon calcitonin.

> PubMed lists PMID 9312206 in Calcified tissue international as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-10 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9312206-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9312206-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-9312206-calcitonin-salmon-v1
- Content SHA-256: `f001eb273c68cc26ebf2bfa56fed36a8e4ab2e248051d582ca8382a06729c34f`

### Claims and source pins

#### Headline

Intrapulmonary drug delivery of salmon calcitonin. ([`pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a`](#source-pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a))

#### Summary

PubMed lists PMID 9312206 in Calcified tissue international as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-10 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a`](#source-pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a))

#### Paragraph 1

PubMed lists PMID 9312206 in Calcified tissue international as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-10 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a`](#source-pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a`](#source-pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a))

### Sources

<a id="source-pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a"></a>
- **Intrapulmonary drug delivery of salmon calcitonin. · retained source version 1:2019-08-31:current:1b7feedc0d3ab2247b40ecf94b2525a143b2b4e087589a27e3291f1c96e70c10** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9312206/) (`pubmed-observation-pmid-9312206-2019-08-31-1b7feedc0d3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Intrapulmonary drug delivery of salmon calcitonin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-9312206-calcitonin-salmon-v1 SHA-256: f001eb273c68cc26ebf2bfa56fed36a8e4ab2e248051d582ca8382a06729c34f.

---

<a id="pubmed-pmid-9640081-calcitonin-salmon-v1"></a>

## \[The influence of salmon calcitonin on the soluble form of VCAM-1 (CD 106) and E-selectin (CD 62E) in serum of patients with atopic bronchial asthma\].

> PubMed lists PMID 9640081 in Polskie Archiwum Medycyny Wewnetrznej as Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 1997-12 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9640081-calcitonin-salmon:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-03-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9640081-calcitonin-salmon/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-9640081-calcitonin-salmon-v1
- Content SHA-256: `627869b86078cece4a7a7991cb84f01789c59b24bb51e6c65c4cf2731861a630`

### Claims and source pins

#### Headline

\[The influence of salmon calcitonin on the soluble form of VCAM-1 (CD 106) and E-selectin (CD 62E) in serum of patients with atopic bronchial asthma\]. ([`pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4`](#source-pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4))

#### Summary

PubMed lists PMID 9640081 in Polskie Archiwum Medycyny Wewnetrznej as Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 1997-12 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4`](#source-pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4))

#### Paragraph 1

PubMed lists PMID 9640081 in Polskie Archiwum Medycyny Wewnetrznej as Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 1997-12 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4`](#source-pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4`](#source-pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4))

### Sources

<a id="source-pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4"></a>
- **\[The influence of salmon calcitonin on the soluble form of VCAM-1 (CD 106) and E-selectin (CD 62E) in serum of patients with atopic bronchial asthma\]. · retained source version 1:2017-03-06:current:a00b82be74c45ebe20622b19cb50c4e1de403f2b9ed2bcf1523da50cbd649381** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9640081/) (`pubmed-observation-pmid-9640081-2017-03-06-a00b82be74c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[The influence of salmon calcitonin on the soluble form of VCAM-1 (CD 106) and E-selectin (CD 62E) in serum of patients with atopic bronchial asthma\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/calcitonin-salmon.json#pubmed-pmid-9640081-calcitonin-salmon-v1 SHA-256: 627869b86078cece4a7a7991cb84f01789c59b24bb51e6c65c4cf2731861a630.

